Cargando…

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial

Detalles Bibliográficos
Autores principales:	Kote-Jarai, Z, Powles, TP, Ashley, S, Easton, DF, Assersohn, L, Sodha, N, Dowsett, M, Gusterson, B, Tidy, A, Mitchell, G, Eeles, RA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2000
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300843/ http://dx.doi.org/10.1186/bcr145

Ejemplares similares

BRCA1, BRCA2 and their possible function in DNA damage response
por: Kote-Jarai, Z, et al.
Publicado: (1999)

Accurate prediction of BRCA1 and BRCA2 heterozygous genotypes using expression profiling of lymphocytes after irradiation-induced DNA damage
por: Kote-Jarai, Z, et al.
Publicado: (2008)

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
por: Mitra, A, et al.
Publicado: (2008)

Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status
por: Killick, Emma, et al.
Publicado: (2014)

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers
por: Kadouri, L, et al.
Publicado: (2004)

Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
por: Phillips, KA, et al.
Publicado: (2012)

Treatment of Epithelioid Sarcoma at the Royal Marsden Hospital
por: Livi, L., et al.
Publicado: (2003)

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
por: Kote-Jarai, Z, et al.
Publicado: (2011)

CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers
por: Kadouri, L, et al.
Publicado: (2001)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers
por: Kadouri, L, et al.
Publicado: (2008)

An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
por: Chenevix-Trench, Georgia, et al.
Publicado: (2007)

Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives
por: Ardern-Jones, Audrey, et al.
Publicado: (2010)

Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers
por: Kote-Jarai, Z, et al.
Publicado: (2006)

Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.
por: Swerdlow, A. J., et al.
Publicado: (1997)

Dr. Marsden
Publicado: (1836)

Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls
por: Locke, Imogen, et al.
Publicado: (2007)

Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations
por: Duffy, S W, et al.
Publicado: (2002)

Genetic testing for BRCA1 and BRCA2 mutations - ready for implementation?
por: Weber, BL
Publicado: (2000)

Genetic Variation of the Brca1 and Brca2 Genes in Macedonian Patients
por: Maleva, I, et al.
Publicado: (2012)

Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers
por: Eeles, Rosalind A
Publicado: (2000)

Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease
por: Saunders, Edward J., et al.
Publicado: (2021)

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
por: Edwards, S M, et al.
Publicado: (2010)

Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience
por: Maruzzo, Marco, et al.
Publicado: (2015)

Breast cancer susceptibility after BRCA1/2: finding the genes and potential practical applications
por: Ponder, BAJ, et al.
Publicado: (2006)

Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America
por: Herzog, Josef S., et al.
Publicado: (2021)

Investigating men’s motivations to engage in genetic screening for BRCA1 and BRCA2 mutations
por: Annoni, Anna Maria, et al.
Publicado: (2022)

Comparison of suspected Lynch syndrome patients carrying BRCA and BRCA‐like variants with Lynch syndrome probands: Phenotypic characteristics and pedigree analyses
por: Xu, Yun, et al.
Publicado: (2020)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience
por: Waddell, T, et al.
Publicado: (2011)

Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital
por: Cunningham, Niamh, et al.
Publicado: (2022)

Dr. Marsden’s Plan of Quarantine
Publicado: (1866)

Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population
por: Wong, Edward S. Y., et al.
Publicado: (2015)

Frequency and Significance of Abnormal Pancreatic Imaging in Patients with BRCA1 and BRCA2 Genetic Mutations
por: Chahla, Elie, et al.
Publicado: (2016)

Advanced topics in BRCA1/BRCA2 analysis by genetic analyzer and real-time PCR
por: Rassi, H
Publicado: (2009)

Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study
por: Mella, Sara, et al.
Publicado: (2017)

In silico analysis of BRCA1 and BRCA2 missense variants and the relevance in molecular genetic testing
por: Poon, Kok-Siong
Publicado: (2021)

Assessing biases of information contained in pedigrees for the classification of BRCA-genetic variants: a study arising from the ENIGMA analytical working group
por: Kerkhofs, C. H. H., et al.
Publicado: (2016)

Ovarian metastases from primary gastrointestinal malignancies: the Royal Marsden Hospital experience and implications for adjuvant treatment.
por: Taylor, A. E., et al.
Publicado: (1995)

The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
por: Crawley, C., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_qsocebuih3moedh26jagqr4rd5